Similarly, 60% (n=9) of patients in age group 50–69y with prostatic adenocarcinoma showed positive overexpression of EMA protein, whereas 40% (n=6) exhibited negative expression and 90% (n=18) of patients in age group 70–89y with prostatic adenocarcinoma showed positive overexpression of EMA protein whereas 10% (n=2) exhibited negative expression. The gene discussed is MUC1; the disease is prostate adenocarcinoma.